Tocilizumab therapy in rheumatoid arthritis with interstitial lung disease : a multicentre retrospective study
© 2019 Royal Australasian College of Physicians..
BACKGROUND: Interstitial lung disease (ILD) is the most severe extra-articular manifestation of rheumatoid arthritis (RA). Although it is responsible of 10-20% of all RA mortality, no controlled studies are available for the treatment of RA-ILD and its therapeutic approach is still debated.
AIMS: To analyse the evolution of ILD in a population of RA patients treated with tocilizumab (TCZ).
METHODS: In this national multicentre study, we retrospectively collected patients with RA-ILD treated with at least one dose of TCZ. For each patient, disease activity and serological data were evaluated. Moreover, we analysed the evolution of high-resolution computed tomography (HRCT) and pulmonary function tests, including forced vital capacity (FVC) and diffusing capacity of the lung for carbon monoxide (DLCO).
RESULTS: Twenty-eight RA-ILD patients were identified (females/males 18/10, mean age 61.6 years), with a mean follow up for TCZ therapy of 30 months. At the end of follow up, FVC remained stable in 14 (56%) patients, improved in 5 (20%) and worsened in 6 (24%). DLCO remained stable in 14 (56%) patients, improved in 5 (20%) and worsened in 6 (24%), even though in 3 patients DLCO and FVC showed an opposite trend. HRCT remained stable in the majority (25) of cases, worsened in two patients with a usual interstitial pneumonia pattern and improved in only one case with a non-specific interstitial pneumonia pattern.
CONCLUSIONS: The management of RA-ILD patients remains a critical unmet need. TCZ demonstrated a good safety profile in patients with RA-ILD and a potential effect on the stabilisation of lung involvement.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:50 |
|---|---|
| Enthalten in: |
Internal medicine journal - 50(2020), 9 vom: 15. Sept., Seite 1085-1090 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Manfredi, Andreina [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antibodies, Monoclonal, Humanized |
|---|
| Anmerkungen: |
Date Completed 27.04.2021 Date Revised 27.04.2021 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1111/imj.14670 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM302658602 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM302658602 | ||
| 003 | DE-627 | ||
| 005 | 20231225111202.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/imj.14670 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1008.xml |
| 035 | |a (DE-627)NLM302658602 | ||
| 035 | |a (NLM)31661185 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Manfredi, Andreina |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Tocilizumab therapy in rheumatoid arthritis with interstitial lung disease |b a multicentre retrospective study |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 27.04.2021 | ||
| 500 | |a Date Revised 27.04.2021 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2019 Royal Australasian College of Physicians. | ||
| 520 | |a BACKGROUND: Interstitial lung disease (ILD) is the most severe extra-articular manifestation of rheumatoid arthritis (RA). Although it is responsible of 10-20% of all RA mortality, no controlled studies are available for the treatment of RA-ILD and its therapeutic approach is still debated | ||
| 520 | |a AIMS: To analyse the evolution of ILD in a population of RA patients treated with tocilizumab (TCZ) | ||
| 520 | |a METHODS: In this national multicentre study, we retrospectively collected patients with RA-ILD treated with at least one dose of TCZ. For each patient, disease activity and serological data were evaluated. Moreover, we analysed the evolution of high-resolution computed tomography (HRCT) and pulmonary function tests, including forced vital capacity (FVC) and diffusing capacity of the lung for carbon monoxide (DLCO) | ||
| 520 | |a RESULTS: Twenty-eight RA-ILD patients were identified (females/males 18/10, mean age 61.6 years), with a mean follow up for TCZ therapy of 30 months. At the end of follow up, FVC remained stable in 14 (56%) patients, improved in 5 (20%) and worsened in 6 (24%). DLCO remained stable in 14 (56%) patients, improved in 5 (20%) and worsened in 6 (24%), even though in 3 patients DLCO and FVC showed an opposite trend. HRCT remained stable in the majority (25) of cases, worsened in two patients with a usual interstitial pneumonia pattern and improved in only one case with a non-specific interstitial pneumonia pattern | ||
| 520 | |a CONCLUSIONS: The management of RA-ILD patients remains a critical unmet need. TCZ demonstrated a good safety profile in patients with RA-ILD and a potential effect on the stabilisation of lung involvement | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a DMARD | |
| 650 | 4 | |a interstitial lung disease | |
| 650 | 4 | |a rheumatoid arthritis | |
| 650 | 4 | |a therapy | |
| 650 | 4 | |a tocilizumab | |
| 650 | 7 | |a Antibodies, Monoclonal, Humanized |2 NLM | |
| 650 | 7 | |a tocilizumab |2 NLM | |
| 650 | 7 | |a I031V2H011 |2 NLM | |
| 700 | 1 | |a Cassone, Giulia |e verfasserin |4 aut | |
| 700 | 1 | |a Furini, Federica |e verfasserin |4 aut | |
| 700 | 1 | |a Gremese, Elisa |e verfasserin |4 aut | |
| 700 | 1 | |a Venerito, Vincenzo |e verfasserin |4 aut | |
| 700 | 1 | |a Atzeni, Fabiola |e verfasserin |4 aut | |
| 700 | 1 | |a Arrigoni, Eugenio |e verfasserin |4 aut | |
| 700 | 1 | |a Della Casa, Giovanni |e verfasserin |4 aut | |
| 700 | 1 | |a Cerri, Stefania |e verfasserin |4 aut | |
| 700 | 1 | |a Govoni, Marcello |e verfasserin |4 aut | |
| 700 | 1 | |a Petricca, Luca |e verfasserin |4 aut | |
| 700 | 1 | |a Iannone, Florenzo |e verfasserin |4 aut | |
| 700 | 1 | |a Salvarani, Carlo |e verfasserin |4 aut | |
| 700 | 1 | |a Sebastiani, Marco |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Internal medicine journal |d 2001 |g 50(2020), 9 vom: 15. Sept., Seite 1085-1090 |w (DE-627)NLM113582811 |x 1445-5994 |7 nnns |
| 773 | 1 | 8 | |g volume:50 |g year:2020 |g number:9 |g day:15 |g month:09 |g pages:1085-1090 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/imj.14670 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 50 |j 2020 |e 9 |b 15 |c 09 |h 1085-1090 | ||